chemotherapy (5)
survival (4)
prognosis (3)
progression-free survival (3)
Adenocarcinoma (2)
Bevacizumab (2)
Chemotherapy (2)
colorectal cancer (2)
induction (2)
neoplasm metastasis (2)
post progression survival (2)
Predictive and prognostic factors (2)
real-world study (2)
renal cell carcinoma (2)
Sorafenib (2)
Sunitinib (2)
Survival (2)
thyroid carcinoma (2)
triple-negative breast cancer (2)
abiraterone acetate (1)
adjuvant (1)
ampullary carcinoma (1)
Androgen deprivation therapy (1)
Bladder cancer (1)
breast cancer (1)
cabozantinib (1)
cancer (1)
capecitabine (1)
CDK4/6 inhibitors (1)
chemoradiotherapy (1)
Chemoradiotherapy (1)
Colon cancer (1)
Colorectal cancer (1)
comparison (1)
consolidation (1)
Cyclin-dependent kinase (CDK) 4/6 inhibitors (1)
De novo brain metastases (1)
delta HALP score (1)
docetaxel + cisplatin + 5-fluorouracil regimen (1)
doxorubicin-ifosfamide (1)
Doxorubicin-ifosfamide (1)
early recurrence (1)
EGFR mutation (1)
enzalutamide (1)
epidermal growth factor receptor (1)
extrapulmonary small cell carcinoma (1)
first-line (1)
First-line chemotherapy (1)
FOLFIRI plus bevacizumab (1)
gastric cancer (1)
Gemcitabine (1)
gemcitabine-docetaxel (1)
Gemcitabine-docetaxel (1)
germ cell tumor (1)
Glioblastoma (1)
GRIm score (1)
Guillain-Barre sydrome (1)
HBV reactivation (1)
HCC (1)
hemoglobin-albumin-lymphocyte-platelet (HALP) score (1)
Her-2 (1)
HER2 low (1)
HER2 status (1)
HER2 zero (1)
HER2-low (1)
histopathology (1)
HRAS (1)
HR-positive breast cancer (1)
Hypothyroidism (1)
Induction chemotherapy (1)
immunosuppressive therapy (1)
incidence (1)
intracardiac metastasis (1)
Ki-67 (1)
Ki-67 index (1)
K-ras (1)
KRAS (1)
KRAS mutation (1)
lanreotide (1)
late recurrence (1)
Late recurrence (1)
Left-sided colon cancers (1)
Lobular carcinoma (1)
locally advanced rectal cancer (1)
Lung adenocarcinoma (1)
lymphovascular invasion (1)
major salivary gland (1)
Malnutrition (1)
Metachronous (1)
metastatic (1)
Metastatic (1)
Metastatic colorectal cancer (1)
metastatic gastric cancer (1)
metastatic hormone-sensitive prostate cancer (1)
Metastatic renal cell cancer (1)
metastatic renal cell carcinoma (1)
metastatic soft tissue sarcoma (1)
Metastatic soft tissue sarcoma (1)
minor salivary gland (1)
molecular testing (1)
mortality (1)
multiple primary tumors (1)
nasopharyngeal cancer (1)
Nasopharyngeal carcinoma (1)
Neoadjuvant chemotherapy (1)
neuroendocrine tumor (1)
neuropathy (1)
nivolumab (1)
non small cell lung cancer (1)
non-clear cell renal cell carcinoma (1)
Non-ductal breast cancer (1)
nonuterine leiomyosarcoma (1)
NRAS (1)
octreotide (1)
Oncogene-driven advanced non-small cell lung cancer (1)
orbit (1)
orbital metastasis (1)
ovarian cancer (1)
Ovarian cancer (1)
overall survival (1)
overall survival performance status (1)
oxaliplatin + 5-fluorouracil + leucovorin regimen (1)
Pancreatic adenocarcinoma (1)
pancreatic neuroendocrine tumor (1)
pathological complete response (1)
Primary tumor resection (1)
Prognosis (1)
prognostic (1)
prognostic biomarker (1)
Prognostic factor (1)
Prognostic Nutritional Index (1)
prostate cancer (1)
protein kinase inhibitors (1)
Psoas muscle area (1)
real-world data (1)
Real-world study (1)
Renal cell carcinoma (1)
residual tumor (1)
Right-sided colon cancers (1)
sacituzumab govitecan (1)
salivary gland cancers (1)
sarcomatoid (1)
Sarcopenia (1)
second-line therapy (1)
second-line treatment (1)
Single agent (1)
small cell lung cancer (1)
Small cell lung cancer (1)
smoking (1)
somatostatin analog (1)
specific KRAS mutation (1)
Stage III (1)
sunitinib (1)
surgery (1)
survival outcomes (1)
Survival related parameters (1)
synchronous (1)
targeted therapy (1)
total neoadjuvant therapy (1)
transitional cell carcinoma (1)
treatment sequence (1)
tumor location (1)
Uterine leiomyosarcoma (1)
XELOX plus bevacizumab (1)
